Community post

Lorenz Leitner (Balgrist University Hospital, Switzerland) and colleagues published a new paper in The Lancet Infectious Diseases on the results of a randomised, placebo-controlled, double-blind clinical trial to investigate intravesical phage therapy using the Eliava Institute's Pyophage cocktail for UTIs in transurethral prostate resection patients. They showed non-inferiority and a favourable safety profile for the phage treatment compared to antibiotics, though phage was not superior to placebo bladder irrigation.